Abstract
The human 5-hydroxytryptamine receptor subtype 1A (5-HT1A) is highly expressed in the raphe nuclei region and limbic structures; for that reason 5-HT1A has served as a promising target for treating human mood disorders and neurodegenerative diseases. We have developed binary quantitative structure-activity relationship (QSAR) models for 5- HT1A binding using data retrieved from the WOMBAT database and the k-Nearest Neighbor (kNN) machine learning method. A rigorous QSAR modeling and screening workflow had been followed, with extensive internal and external validation processes. The models’ classification accuracies to discriminate 5-HT1A binders from the non-binders are as high as 96% for the external validation. These models were employed further to mine two major natural products screening libraries, i.e. TimTec Natural Product Library (NPL) and Natural Derivatives Library (NDL). In the end five screening hits were tested by radioligand binding assays with a success rate of 40%, and two Library compounds were confirmed to be binders at the μM concentration against the human 5-HT1A receptor. The combined application of rigorous QSAR modeling and model-based virtual screening presents a powerful means for profiling natural products compounds with important biomedical activities.
Keywords: 5-HT1A receptor, external validation, high-throughput screening, natural products, bioactivity profiling, QSAR.
Combinatorial Chemistry & High Throughput Screening
Title:Discovery of Natural Product-Derived 5-HT1A Receptor Binders by Cheminfomatics Modeling of Known Binders, High Throughput Screening and Experimental Validation
Volume: 18 Issue: 7
Author(s): Man Luo, Terry-Elinor Reid and Xiang Simon Wang
Affiliation:
Keywords: 5-HT1A receptor, external validation, high-throughput screening, natural products, bioactivity profiling, QSAR.
Abstract: The human 5-hydroxytryptamine receptor subtype 1A (5-HT1A) is highly expressed in the raphe nuclei region and limbic structures; for that reason 5-HT1A has served as a promising target for treating human mood disorders and neurodegenerative diseases. We have developed binary quantitative structure-activity relationship (QSAR) models for 5- HT1A binding using data retrieved from the WOMBAT database and the k-Nearest Neighbor (kNN) machine learning method. A rigorous QSAR modeling and screening workflow had been followed, with extensive internal and external validation processes. The models’ classification accuracies to discriminate 5-HT1A binders from the non-binders are as high as 96% for the external validation. These models were employed further to mine two major natural products screening libraries, i.e. TimTec Natural Product Library (NPL) and Natural Derivatives Library (NDL). In the end five screening hits were tested by radioligand binding assays with a success rate of 40%, and two Library compounds were confirmed to be binders at the μM concentration against the human 5-HT1A receptor. The combined application of rigorous QSAR modeling and model-based virtual screening presents a powerful means for profiling natural products compounds with important biomedical activities.
Export Options
About this article
Cite this article as:
Luo Man, Reid Terry-Elinor and Wang Simon Xiang, Discovery of Natural Product-Derived 5-HT1A Receptor Binders by Cheminfomatics Modeling of Known Binders, High Throughput Screening and Experimental Validation, Combinatorial Chemistry & High Throughput Screening 2015; 18 (7) . https://dx.doi.org/10.2174/1386207318666150703113948
DOI https://dx.doi.org/10.2174/1386207318666150703113948 |
Print ISSN 1386-2073 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5402 |
Call for Papers in Thematic Issues
Artificial Intelligence Methods for Biomedical, Biochemical and Bioinformatics Problems
Recently, a large number of technologies based on artificial intelligence have been developed and applied to solve a diverse range of problems in the areas of biomedical, biochemical and bioinformatics problems. By utilizing powerful computing resources and massive amounts of data, methods based on artificial intelligence can significantly improve the ...read more
Eco-friendly Agents for Biological Control of Pathogenic Diseases
The discovery of an alternative biological approach to disease management includes work on medicinal products derived from natural sources as a starting point for the development of eco-friendly agents for these diseases and the injuries they cause, as well as reducing human contact with hazardous chemicals and their residues. We ...read more
Emerging trends in diseases mechanisms, noble drug targets and therapeutic strategies: focus on immunological and inflammatory disorders
Recently infectious and inflammatory diseases have been a key concern worldwide due to tremendous morbidity and mortality world Wide. Recent, nCOVID-9 pandemic is a good example for the emerging infectious disease outbreak. The world is facing many emerging and re-emerging diseases out breaks at present however, there is huge lack ...read more
Exploring Spectral Graph Theory in Combinatorial Chemistry
Scope of the Thematic Issue: Combinatorial chemistry involves the synthesis and analysis of a large number of diverse compounds simultaneously. Traditional methods rely on brute force experimentation, which can be time-consuming and resource-intensive. Spectral Graph Theory, a branch of mathematics dealing with the properties of graphs in relation to the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neuroprotection by Alpha 2-Adrenergic Agonists in Cerebral Ischemia
Current Neuropharmacology Cardioprotective Effects and <i>in-silico</i> Antioxidant Mechanism of L-Ergothioneine in Experimental Type-2 Diabetic Rats
Cardiovascular & Hematological Agents in Medicinal Chemistry Antiprotozoal Agents: An Overview
Anti-Infective Agents in Medicinal Chemistry Myelodysplastic Syndromes: Review of Pathophysiology and Current Novel Treatment Approaches
Current Cancer Drug Targets Aldosterone to Renin Ratio (ARR) in Clinical use, with Reference to the Primary Care Setting: ARR to Whom, When, How, What for?
Current Hypertension Reviews Atrial Fibrillation in Patients Undergoing Surgical Revascularization: An Update on Pharmacologic Prophylaxis
Cardiovascular & Hematological Agents in Medicinal Chemistry Role of Free Radicals in Sepsis: Antioxidant Therapy
Current Pharmaceutical Design Dendrimers and Dendritic Polymers as Anti-infective Agents: New Antimicrobial Strategies for Therapeutic Drugs
Anti-Infective Agents in Medicinal Chemistry Nutraceuticals for Promoting Longevity
Current Nutraceuticals Stearoyl-CoA Desaturase: A Vital Checkpoint in the Development and Progression of Obesity
Endocrine, Metabolic & Immune Disorders - Drug Targets The Role of Melatonin in Multiple Sclerosis, Huntington's Disease and Cerebral Ischemia
CNS & Neurological Disorders - Drug Targets Drug Therapy for Behavioral and Psychological Symptoms of Dementia
Current Neuropharmacology Pulmonary Arterial Hypertension: Need to Treat
Inflammation & Allergy - Drug Targets (Discontinued) Hydrogen Sulphide: Biopharmacological Roles in the Cardiovascular System and Pharmaceutical Perspectives
Current Medicinal Chemistry Hypotensive Effects of the Triterpene Oleanolic Acid for Cardiovascular Prevention
Current Molecular Pharmacology Organic Antifungal Drugs and Targets of Their Action
Current Topics in Medicinal Chemistry CB1 Cannabinoid Antagonists: Structure-Activity Relationships and Potential Therapeutic Applications
Current Topics in Medicinal Chemistry Antipsychotic Polypharmacy
Current Pharmaceutical Design Therapeutic Challenges in Neuroendocrine Tumors
Anti-Cancer Agents in Medicinal Chemistry The Role of Niacin in Lipid-lowering Treatment: Are we Aiming Too High?
Current Pharmaceutical Design